Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Words To The Wise: Attorneys Analyze FDA’s Case Against Utah Medical

This article was originally published in The Gray Sheet

Executive Summary

An FDA legal official signaled that the agency's recent loss of a device manufacturing compliance case does not mean that the agency will stop going after firms with deficient quality controls - even in cases where there have been no adverse events or failures associated with the firm's products

You may also be interested in...



Utah Medical Seeks Reparations From FDA For Alleged FDA Misconduct

Utah Medical is considering whether to file a lawsuit against FDA after the Department of Health & Human Services denied its "administrative claim" seeking payments and other settlement actions based on alleged misconduct by FDA employees

Utah Medical Seeks Reparations From FDA For Alleged FDA Misconduct

Utah Medical is considering whether to file a lawsuit against FDA after the Department of Health & Human Services denied its "administrative claim" seeking payments and other settlement actions based on alleged misconduct by FDA employees

NuVasive Boosts Artificial Disc Development, Stock; OTC Index Rises 15%

NuVasive will use profits gained from a series of 510(k)-cleared spinal devices to fuel artificial disc and nucleus replacement development in 2006

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel